Analysing the impact of a guideline for the use of new potassium binders for treatment of chronic hyperkalaemia to maximise inhibition of renin–angiotensin–aldosterone system (RAAS) within the general nephrology clinic?

Abstract excerpt

<title>Abstract</title> <p>Background Renin–angiotensin–aldosterone system (RAAS) inhibitors provide significant cardiorenal benefits with improved long-term outcomes for patients. This is most significant for patients receiving maximal RAAS inhibition, but some patients are unable to tolerate this therapy because of hyperkalaemia. Recently published National Institute for Health and Care Excellence (NICE) techno...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Kidney Injury
• Biomedical Research
• Chronic Disease
• Congresses as Topic
• Dialysis and Renal Disease Management
• Disease Management
• Genetic Predisposition to Disease
• Renal Insufficiency, Chronic

Identifiers and source

Literature Corpus work

4b4e5df2-d2bb-5cbe-91ce-1a0f39b5fc03

DOI

10.21203/rs.3.rs-56113/v1